NuCana plc (NCNA)
| Market Cap | 4.27M -61.9% |
| Revenue (ttm) | n/a |
| Net Income | -12.88M |
| EPS | -3.17 |
| Shares Out | 4.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,275 |
| Open | 1.0200 |
| Previous Close | 1.0200 |
| Day's Range | 0.9700 - 1.0300 |
| 52-Week Range | 0.9484 - 5.6500 |
| Beta | 2.31 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study... [Read more]
News
NuCana announces grant of composition-of-matter patent for NUC-7738 in Europe
NuCana (NCNA) announced that the European Patent Office, EPO, has granted an important patent covering the composition of matter for NUC-7738. This patent is a key component of the patent…
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent co...
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURG...
NuCana appoints Ian Webster as CFO
NuCana (NCNA) announced the appointment of Ian Webster as CFO, effective immediately. Ian has served as interim CFO since June 2025 and was previously director of finance since joining NuCana…
NuCana Appoints Ian Webster as Chief Financial Officer
EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatm...
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination ...
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
NuCana appoints Bruce as COO
NuCana (NCNA) announced the appointment of Theresa Bruce as Chief Operating Officer, COO, effective January 1, 2026. Bruce previously served as Chief Operating Officer at Nexus Oncology Published firs...
NuCana Appoints Theresa Bruce as Chief Operating Officer
EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on improving treatment outcomes f...
NuCana presents latest clinical data at ESMO 2025 on NUC-7738
NuCana (NCNA) presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 ...
NuCana presents data at ESMO on NUC-7738
NuCana (NCNA) presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 ...
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings Data Presented at ESMO IO 2025 include Partial Responses, Dur...
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued List...
NuCana announces grant of composition-of-matter patent for NUC-7738 in China
NuCana (NCNA) announced that the China National Intellectual Property Administration, CNIPA, has granted an important patent covering the composition of matter for NUC-7738. This patent is expected to...
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has ...
NuCana presents data at ESMO 2025 for NUC-7738, PD-1 inhibitors
NuCana (NCNA) presented data at the European Society for Medical Oncology Congress 2025, ESMO, on a new model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary…
NuCana announces publication of new data for NUC-3373
NuCana (NCNA) announced the publication of new data on NUC-3373. The update includes results from the NuTide:303 clinical study, published on medRxiv, the preprint server for health sciences, together...
NuCana compliant with all Nasdaq continued listing criteria
NuCana (NCNA) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued…
NuCana Compliant with All Nasdaq Continued Listing Criteria
EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on S...
NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncolog...
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
NuCana PLC (ADR) trading halted, news pending
19:50 EDT NuCana (NCNA) PLC (ADR) trading halted, news pending
NuCana announces ADS ratio change
NuCana (NCNA) announces that it will implement the company’s previously disclosed plans to change the ratio of its American Depository Shares to its ordinary shares from one ADS, representing twenty-f...
NuCana Announces ADS Ratio Change
EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company's previously disclosed plans to change t...
NuCana cancels all outstanding Series A Warrants
NuCana (NCNA) canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A…